Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Dorit Breining"'
Autor:
Andy Göbel, Jan D. Kuhlmann, Theresa Link, Pauline Wimberger, Cornelia Link-Rachner, Stefanie Thiele, Stefania Dell'Endice, Giulia Furesi, Dorit Breining, Martina Rauner, Lorenz C. Hofbauer, Tilman D. Rachner
Publikováno v:
Journal of Bone Oncology, Vol 16, Iss , Pp - (2019)
Background: Semaphorin 4D (Sema4D) is a glycoprotein that inhibits bone formation and has been associated with cancer progression and the occurrence of bone metastases. Recently, Sema4D expression has been linked to estrogen signaling in breast cance
Externí odkaz:
https://doaj.org/article/cd0e1a00e9d747cba09000e5c9236658
Autor:
Dorit Breining, Sabine Kasimir-Bauer, Oliver Hoffmann, Tilman D. Rachner, Rainer Kimmig, Kati Erdmann, Ann-Kathrin Bittner, Lorenz C. Hofbauer, Andy Göbel
Publikováno v:
Breast Cancer Research and Treatment. 180:515-524
Periostin is a secreted extracellular matrix protein, which was originally described in osteoblasts. It supports osteoblastic differentiation and bone formation and has been implicated in the pathogenesis of several human malignancies, including brea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eed26ed0c1a2a7f3ddd527f62b9411cc
https://doi.org/10.1007/s10549-020-05570-0
https://doi.org/10.1007/s10549-020-05570-0
Publikováno v:
Cell Death & Disease
Cell Death and Disease, Vol 10, Iss 2, Pp 1-12 (2019)
Cell Death and Disease, Vol 10, Iss 2, Pp 1-12 (2019)
The mevalonate pathway has emerged as a promising target for several solid tumors. Statins are inhibitors of the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme of this pathway, and are commonly used to treat patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccc7ef6fd0f8fcfc72abc2802b72b81c
https://pubmed.ncbi.nlm.nih.gov/30692522
https://pubmed.ncbi.nlm.nih.gov/30692522
Autor:
Pauline Wimberger, Theresa Link, Martina Rauner, Cornelia S. Link-Rachner, Stefanie Thiele, Dorit Breining, Tilman D. Rachner, Lorenz C. Hofbauer, Andy Göbel, Stefania Dell'Endice, Giulia Furesi, Jan Dominik Kuhlmann
Publikováno v:
Journal of Bone Oncology, Vol 16, Iss, Pp-(2019)
Background: Semaphorin 4D (Sema4D) is a glycoprotein that inhibits bone formation and has been associated with cancer progression and the occurrence of bone metastases. Recently, Sema4D expression has been linked to estrogen signaling in breast cance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bc08caec3713f775e3f32111a5a1c1c
https://doi.org/10.1016/j.jbo.2019.100237
https://doi.org/10.1016/j.jbo.2019.100237